IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Amary, M Fernanda, Bacsi, Krisztian, Maggiani, Francesca, Damato, Stephen, Halai, Dina, Berisha, Fitim, Pollock, Robin, O'Donnell, Paul +8 more·2011·The Journal of Pathology
DOI 10.1002/path.2913

Cited by (1,000)

Items 601–700 of 1,000

  1. Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability
    Joanne M. Kingsbury, Nachiketha Shamaprasad, R. Blake Billmyre, Joseph Heitman, Maria Elena Cardenas · 2016 · Human Molecular Genetics
  2. Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening
    Chujiao Hu, Zhirui Zeng, Dan Ma, Zhi-Xin Yin, Shanshan Zhao, Tengxiang Chen, Lei Tang, Shi Zuo · 2022 · Frontiers in Pharmacology
  3. Japanese orthopaedic association (JOA) clinical practice guideline on the management of primary malignant bone tumors - Secondary publication
    Kazuaki Tsuchiya, Toshihiro Akisue, Shigeru Ehara, Akira Kawai, Hirotaka Kawano, Hiroaki Hiraga, Ako Hosono, Hiroyuki Hutani, Takeshi Morii, Hideo Morioka et al. · 2024 · Journal of Orthopaedic Science
  4. Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature
    Georgian Longin Iacobescu, Antonio-Daniel Corlatescu, Bogdan Şerban, Razvan Spiridonica, Horia Petre Costin, Cătălin Cîrstoiu · 2024 · Current Issues in Molecular Biology
  5. Advancing Systemic Therapy in Chondrosarcoma: New Horizons
    Ka Hou C. Li, Ashish Gulia, Florence Duffaud, Robin L. Jones · 2024 · Oncology and Therapy
  6. Immunohistochemistry using monoclonal antibody MsMab‐2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma
    Akimasa Hayashi, Kento Misumi, Junji Shibahara, Norihiro Kokudo, Yukinari Kato, Masashi Fukayama · 2016 · Pathology International
  7. Clinical, Radiological, and Histopathological Characteristics of Periosteal Chondrosarcoma with a Focus on the Frequency of Medullary Invasion
    Makoto Nakagawa, Makoto Endo, Yosuke Susuki, Nobuhiko Yokoyama, Akira Maekawa, Akira Nabeshima, Keiichiro Iida, Toshifumi Fujiwara, Nokitaka Setsu, Tomoya Matsunobu et al. · 2022 · Journal of Clinical Medicine
  8. Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas
    Artem I. Batalov, Natalia E. Zakharova, Ivan Vladimirovich Chekhonin, Eduard L. Pogosbekyan, Anna V. Sudarikova, Sergey A. Goryainov, Anna A. Shulgina, Artem Yu. Belyaev, Dmirti Yu. Usachev, Igor Pronin · 2022 · Diagnostics
  9. Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?
    Jacob G. Scott, David Basanta, Prakash Chinnaiyan, Peter Canoll, Kristin R. Swanson, Alexander R.A. Anderson · 2011 · Neuro-Oncology
  10. BICD1expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas
    Shang-Pen Huang, Yu‐Chan Chang, Qie Hua Low, Alexander T.H. Wu, Chi‐Long Chen, Yuan‐Feng Lin, Michael Hsiao · 2017 · Oncotarget
  11. IDH2-Deficient Mice Develop Spinal Deformities With Aging
    Unbin Chae, Na Rae Park, Eunjin Kim, J.-Y. CHOI, Mijung Yim, Heejin Lee, Sang‐Rae Lee, Sunghee Lee, Junhee Park, Dong‐Seok Lee · 2018 · Physiological Research
  12. Do Patient-derived Spheroid Culture Models Have Relevance in Chondrosarcoma Research?
    Rui‐Chen Ma, Jonathan Brendan Mandell, Feiqi Lu, Tanya E. Heim, Karen Elizabeth Schoedel, Anette U. Duensing, Rebecca Jean Watters, Kurt Richard Weiss · 2020 · Clinical Orthopaedics and Related Research
  13. Association of Clinicopathological Features With Outcome in Chondrosarcomas of the Head and Neck
    Sofia Asioli, Poosit Ruengwanichayakun, Matteo Zoli, Federica Guaraldi, Giacomo Sollini, Paolo Greco, Carla Facco, Dino Gibertoni, Brayan Vega Jiménez, Stefania Benini et al. · 2020 · Otolaryngology
  14. Brain Gliomas and Ollier Disease: Molecular Findings as Predictive Risk Factors?
    Sergio Corvino, Giuseppe Mariniello, Giuseppe Corazzelli, Raduan Ahmed Franca, Marialaura Del Basso De, Rosa Della Monica, Lorenzo Chiariotti, Francesco Maiuri · 2022 · Cancers
  15. Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs
    Albert Roessner, Sabine Franke, Julian Schreier, Sarah Rebecca Ullmann, Franziska Karras, Dörthe Jechorek · 2022 · Pathology - Research and Practice
  16. Conventional chondrosarcoma: old controversies and new insights
    Jodi M. Carter, Carrie Y. Inwards · 2014 · Diagnostic histopathology
  17. Exploring the key genes and pathways in enchondromas using a gene expression microarray
    Zhongju Shi, Hengxing Zhou, Bin Pan, Lu Lu, Yi Kang, Lu Liu, Zhijian Wei, Shiqing Feng · 2017 · Oncotarget
  18. Giant Cell Tumor of Bone With Cartilage Matrix
    Iva Brčić, Feisal Yamani, Carrie Y. Inwards, Vaiyapuri P. Sumathi, Leslie G. Dodd, Portia A. Kreiger, Kesavan Sittampalam, Ted R. Allred, Karl Kashofer, Bernadette Liegl‐Atzwanger et al. · 2020 · The American Journal of Surgical Pathology
  19. Tumors of the central nervous system
    Peiguo G. Chu, Lawrence Martin Weiss · 2000 · Cambridge University Press eBooks
  20. Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens
    Darwin W. Kwok, Nicholas O. Stevers, Takahide Nejo, Lee H. Chen, Iñaki Etxeberría, Jangham Jung, Kaori Okada, Maggie Colton Cove, Senthilnath Lakshmanachetty, Marco Gallus et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  21. Update of cartilaginous tumours according to the WHO classification 2020
    S. Gómez-Peña, Alexandro Eusebio, Juan Arrazola García, P. Romero Fernández, M.J. Moreno Casado, Ana María Crespo Rodríguez · 2024 · Radiología (English Edition)
  22. α-methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas
    Sarit Aviel‐Ronen, Oranit Zadok, Aya Vituri, Dvora Nass, Ignat Schwartz, Camila Avivi, Iris Barshack · 2016 · Scientific Reports
  23. Soft Tissue Special Issue: Chondroid Neoplasms of the Skull
    Ashley N. Flaman, Jason K. Wasserman, Denis H. Gravel, Bibianna Purgina · 2020 · Head and Neck Pathology
  24. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma
    Nancy M. Joseph, Kevin C. McGill, Andrew Horvai · 2020 · The American Journal of Surgical Pathology
  25. Pyridine ring as an important scaffold in anticancer drugs
    Amr Elagamy, Laila K. Elghoneimy, Reem K. Arafa · 2022 · Elsevier eBooks
  26. Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas
    Ioannis Panagopoulos, Ludmila Gorunova, Ingeborg Taksdal, Bodil Bjerkehagen, Sverre Heim · 2015 · Oncology Letters
  27. Endoscopic Endonasal Approach in Skull Base Chondrosarcoma Associated with Maffucci Syndrome: Case Series and Literature Review
    André Luiz Beer-Furlan, Leonardo L. Balsalobre, Eduardo Vellutini, Aldo Cassol Stamm · 2015 · World Neurosurgery
  28. An overview of current and future treatment options for chondrosarcoma
    Chen‐Ming Su, Yi‐Chin Fong, Chih‐Hsin Tang · 2014 · Expert Opinion on Orphan Drugs
  29. Glioblastoma and acute myeloid leukemia: malignancies with striking similarities
    Eric A. Goethe, Bing Z. Carter, Ganesh Rao, Naveen Pemmaraju · 2017 · Journal of Neuro-Oncology
  30. 3D-QSAR, molecular docking and molecular dynamics simulations study of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives to explore the structure requirements of mutant IDH1 inhibitors
    Kun Yao, Pengyu Liu, Haipeng Liu, Qingyun Wei, Jie Yang, Peng Cao, Yisheng Lai · 2019 · Journal of Molecular Structure
  31. An overview of chondrosarcoma with a focus on nanoscale therapeutics
    Dong Hyun Kim, Han Sol Lee, Yong‐Hyeon Mun, Seokjin Koh, Joon-Sun Park, Sang Min Lee, Nae-Won Kang, Mee Yeon Lee, Cheong‐Weon Cho, Dae‐Duk Kim et al. · 2020 · Journal of Pharmaceutical Investigation
  32. Mutational status of IDH1 in uveal melanoma
    Patrick Joseph Cimino, Yungtai Kung, Joshua I. Warrick, Shu-Hong Chang, Christopher Dirk Keene · 2016 · Experimental and Molecular Pathology
  33. Beyond the Oncogene Revolution: Four New Ways to Combat Cancer
    Thorsten Berger, Mary E. Saunders, Tak W. Mak · 2016 · Cold Spring Harbor Symposia on Quantitative Biology
  34. Soft Tissue and Bone Tumor Diagnostics: Harnessing the Power of Molecular Techniques
    Fleur Cordier, Liesbeth Ferdinande, Anne Hoorens, Koen K Van de Vijver, Jo Van Dorpe, David Creytens · 2023 · Genes
  35. Chitosan Nanoparticle-Mediated Delivery of Alstonia venenata R.Br. Root Methanolic Extract: A Promising Strategy for Breast Cancer Therapy in DMBA-Induced Breast Cancer in Sprague Dawley Rats
    Aarthi Jeganathan, Karuppusamy Arunachalam, Anju Byju, Anju Rani George, Sradha Sajeev, Kavimani Thangasamy, Natesan Geetha · 2024 · Antioxidants
  36. Chondrosarcoma: Clinical Behavior, Molecular Mechanisms, and Emerging Therapeutic Strategies.
    M. Agulnik, B. Wilky, Steven W. Thorpe Facs, Lee M. Zuckerman · 2025 · Critical reviews in oncology/hematology
  37. Juvenile granulosa cell tumor associated with Ollier disease
    Laurel A. Littrell, Carrie Y. Inwards, Florette K. Hazard, Doris E. Wenger · 2022 · Skeletal Radiology
  38. Benign and low-grade cartilaginous tumors: an update on differential diagnosis
    Cemile Dilara Savci-Heijink, Arjen H.G. Cleven, Judith V.M.G. Bovée · 2022 · Diagnostic histopathology
  39. Towards a metabolic therapy of cancer?
    Martina Chiu, Laura Ottaviani, Massimiliano Giovanni Bianchi, R. Franchi‐Gazzola, Ovidio Bussolati · 2012 · Acta bio-medica dell'Ateneo parmense/Acta biomedica
  40. Novel Treatment Targets in Sarcoma: More Than Just the GIST
    Alexander Noor Shoushtari, Brian Andrew Van Tine, Gary K. Schwartz · 2014 · American Society of Clinical Oncology Educational Book
  41. Knorpeltumoren: Morphologie, Genetik und Basisaspekte der Targettherapie
    Albert Roessner, Maria Anna Smolle, Victor Schoeder, Johannes Haybaeck · 2020 · Der Pathologe
  42. Oncometabolites as Regulators of DNA Damage Response and Repair
    Susan E. Gueble, Ranjit S. Bindra · 2021 · Seminars in Radiation Oncology
  43. Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mIDH1 Mutant Tumours
    Valérie Weber, Lucie Arnaud, Sladjana Dukić-Stefanović, Barbara Wenzel, Valérie Roux, Jean‐Michel Chezal, Thu Hang Lai, Rodrigo Teodoro, Klaus Kopka, Élisabeth Miot-Noirault et al. · 2022 · Molecules
  44. Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma
    Nasrin Shayanfar, Ali Zare‐Mirzaie, Mahsa Mohammadpour, Ensieh Jafari, Amirhosein Mehrtash, Nikoo Emtiazi, Fatemeh Tajik · 2022 · Journal of Cancer Research and Clinical Oncology
  45. Proteomic Analysis of a Nasopharyngeal Carcinoma Cell Line and a Nasopharyngeal Epithelial Cell Line
    Pei‐Yu Huang, Tingting Zeng, Meng-Qing Li, Xiaojiao Ban, Ying-Hui Zhu, Baozhu Zhang, Hai‐Qiang Mai, Li Zhang, Xin‐Yuan Guan, Yan Li · 2015 · Tumori Journal
  46. Periosteal chondroma of the distal tibia: Computed tomography and magnetic resonance imaging characteristics and correlation with histological findings
    Jun Nishio, YASUHARU ARASHIRO, SHUN MORI, Hiroshi Iwasaki, Masatoshi Naito · 2015 · Molecular and Clinical Oncology
  47. Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting
    AML is a heterogeneous hematologic malignancy, characterized by the accumulation of various somatic genetic abnormalities and of immature myeloid cells arrested at various stages of maturation. Studies carried out in the last 2 decades have led to the identification of two broad types of genetic mutations, which cooperate to support development of the leukemic process. The class I mutations confer a survival/growth advantage to hematopoietic stem cells (HSCs) and progenitor cells (HPCs), such as the mutations in, the loss of, or the mutations in, receptor tyrosine kinase. The class II mutations promote self-renewal and block the differentiation of HPCs, such as the t(8:21) fusion involving, or the t(15;17) fusion involving · 2016 · Journal of Exploratory Research in Pharmacology
  48. Pathology of Chordoma and Chondrosarcoma of the Axial Skeleton
    Darcy A. Kerr, Andrew Eric Rosenberg · 2017 · Elsevier eBooks
  49. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma
    Keisuke Miyake, Yoshifumi Baba, Takatsugu Ishimoto, Yukiharu Hiyoshi, Masaaki Iwatsuki, Yuji Miyamoto, Naoya Yoshida, Masayuki Watanabe, Yoko Ogata, Megumi Nagayama et al. · 2018 · Medical Oncology
  50. IDH-Mutant Gliomas
    Kensuke Tateishi, Tetsuya Yamamoto · 2019 · IntechOpen eBooks
  51. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1)
    Chung Hyo Kang, Sang Un Choi, You Hwa Son, Heung Kyoung Lee, Hye Gwang Jeong, Chang‐Soo Yun, Sunjoo Ahn, Chi Hoon Park · 2020 · Anticancer Research
  52. Primary malignant tumors of bone surface: a review with emphasis in differential diagnosis
    Marina Pacheco, Alberto Righi · 2020 · Journal of Cancer Metastasis and Treatment
  53. Periosteal chondrosarcoma: A case series in a referral center with survivorship analysis
    Marina Pacheco, Lucia Barra, Marco Gambarotti, Giovanna Magagnoli, Marta Sbaraglia, Sofia Asioli, Stefania Cocchi, Elisa Carretta, Tommaso Frisoni, Stefania Benini et al. · 2022 · European Journal of Surgical Oncology
  54. Premalignant Conditions of Bone
    Michael D. Eckhoff, Matthew E. Wells, Osvaldo Padilla, Elizabeth M. Polfer, Christopher J. Castagno, Ahmed M. Thabet, Shaimaa Elzamly, Harry Langford Wilson, Rajiv Rajani · 2022 · JAAOS Global Research and Reviews
  55. MicroRNAs in the pathobiology of sarcomas
    Anne E. Sarver, Subbaya Subramanian · 2015 · Laboratory Investigation
  56. Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation
    Suresh Kumar Raveendran, Santhi Sarojam, Sangeetha Vijay, Chandran Geetha Aswathy, Jayadevan Sreedharan, Geetha Narayanan, Hariharan Sreedharan · 2015 · Asian Pacific Journal of Cancer Prevention
  57. Malignant Cartilage Tumors
    2021 · American Registry of PathologyArlington, Virginia eBooks
  58. Promoter Methylation Analysis of IDH Genes in Human Gliomas
    Simon Flanagan, Maggie C Lee, Cheryl C. Y. Li, Catherine M. Suter, Michael E. Buckland · 2012 · Frontiers in Oncology
  59. Epigenetic regulation of ferroptosis in gastrointestinal cancers (Review)
    Linqiang Gong, Linlin Wu, Shiyuan Zhao, Shuai Xiao, Xue Chu, Yazhou Zhang, Fengfeng Li, Shuhui Li, Hui Yang, Pei Jiang · 2025 · International Journal of Molecular Medicine
  60. IDH mutant high-grade gliomas
    Santosh Valvi, Maryam Fouladi, Michael J. Fisher, Nicholas G. Gottardo · 2025 · Frontiers in Molecular Neuroscience
  61. Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial
    Robin L. Jones, Roman Groisberg, Jean‐Yves Blay, H. Colman, M. De La Fuente, Patricia Roxburgh, Mwe Mwe Chao, Hua Tian, Florence Duffaud, Rastislav Bahleda et al. · 2026 · Nature Communications
  62. Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy
    Karen Elizabeth Schoedel, Tanya E. Heim, Anette U. Duensing, Ines Lohse, Laura Presutti, Rebekah Belayneh, Sumail S. Bhogal, Anya Singh‐Varma, Alexander Chang, Uma R. Chandran et al. · 2024 · Cancers
  63. A perioperative study of Safusidenib in patients with IDH1 -mutated glioma
    Sarah A. Cain, Monique D. Topp, Mark Andrew Rosenthal, Robert Tobler, Saskia Freytag, Sarah A. Best, James Richard Whittle, Katharine Jann Drummond · 2024 · Future Oncology
  64. Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment
    Dominik Juskanič, Jana Poláková Mištinová, Samuel Hollý, Monika Sekerešová, Kamil Koleják, Lukáš Pátrovič · 2022 · Magnetic Resonance Materials in Physics Biology and Medicine
  65. Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care
    Agnes N. Ewongwo, Caressa Hui, Everett James Moding · 2024 · Seminars in Radiation Oncology
  66. Regulatory variation: an emerging vantage point for cancer biology
    Luolan Li, Alireza Lorzadeh, Martin Hirst · 2013 · WIREs Systems Biology and Medicine
  67. Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors
    Annette Bentsen Håvik, Guro Elisabeth Lind, Hilde Honne, Torstein Ragnar Meling, David Scheie, Kirsten Sundby Hall, Eva van den Berg, Fredrik Mertens, Piero Picci, Ragnhild A. Lothe et al. · 2013 · Neuro-Oncology
  68. Dedifferentiated chondrosarcoma of bone with prominent rhabdoid component
    Matthew H. Stemm, Chad J. Beck, Rajeev R. Mannem, John C. Neilson, Michael J. Klein · 2016 · Annals of Diagnostic Pathology
  69. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis
    Ya Gao, Maurice de Wit, Eduard A. Struys, Herma C. Z. van der Linde, Gajja Sophi Salomons, Martine L.M. Lamfers, Rob Willemsen, Peter A.E. Sillevis Smitt, Pim J. French · 2018 · PLoS ONE
  70. Targeted Therapies in the Treatment of Sarcomas
    Brianna Hoffner, ANTHONY D. ELIAS, Victor Manuel Villalobos · 2018 · Targeted Oncology
  71. Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas
    Alberto Pïcca, Anna Luisa Di Stefano, Marc Sanson · 2018 · Current Opinion in Neurology
  72. IDH1 Expression via the R132H Mutation–Specific Antibody in Adrenocortical Neoplasias—Prognostic Impact in Carcinomas
    Mirkka Pennanen, Olli Tynninen, Soili I. Kytölä, Pekka Ellonen, Harri K. Mustonen, Ilkka Heiskanen, Caj H. Haglund, Johanna T. Arola · 2020 · Journal of the Endocrine Society
  73. Histopathology of Parasellar Neoplasms
    Emilija Manojlović-Gačić, Elham Rostami, Niki Karavitaki, Olivera Casar‐Borota · 2020 · Neuroendocrinology
  74. Cancer surveillance in children with Ollier Disease and Maffucci Syndrome
    Manuel Diezi, Pierre‐Yves Zambelli, Andrea Superti‐Furga, Sheila Unger, Raffaele Renella · 2021 · American Journal of Medical Genetics Part A
  75. Genetic characteristics and molecular diagnostics of bone tumors
    David Ilan Suster, Saul M. Suster · 2021 · Journal of Cancer Metastasis and Treatment
  76. Pathological Features of Tumors of the Nervous System in Hereditary Cancer Predisposition Syndromes: A Review
    Saber Tadros, Aleksei Kondrashov, Sriya Namagiri, Ashis K. Chowdhury, Yeshavanth Banasavadi‐Siddegowda, Abhik Ray‐Chaudhury · 2021 · Neurosurgery
  77. Maffucci Syndrome
    Yen‐Po Tsao, Chang‐Youh Tsai, WEI-SHENG CHEN · 2015 · The Journal of Rheumatology
  78. Enasidenib
    Alwin Krämer, Tilmann Bochtler · 2018 · Recent results in cancer research/Recent Results in Cancer Research
  79. Periosteal chondrosarcoma: an unusual juxtacortical sarcoma
    Maxine E. Kresse, Mark J. Kransdorf, Christopher P. Beauchamp, Brandon T. Larsen, Krista A. Goulding · 2022 · Skeletal Radiology
  80. Updates in Primary Bone Tumors
    Xiaohua Qian · 2018 · Surgical pathology clinics
  81. Delineating the nexus between gut-intratumoral microbiome and osteo-immune system in bone metastases
    Shreya Kapoor, Muskan Gupta, Leena Sapra, Taranjeet Kaur, Rupesh Kumar Srivastava · 2024 · Bone Reports
  82. Discovery and structure-activity relationship study of novel hydantoin-based inhibitors targeting mutant isocitrate dehydrogenase 1 (mIDH1)
    Dong Luo, Maojie Zhang, Zizhen Liang, Linling Gan, Yun He, Shaolin Zhang · 2025 · European Journal of Medicinal Chemistry
  83. Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
    William C. H. Cross, Iben Lyskjær, Christopher Davies, Abigail Bunkum, Ana Maia Rocha, Tom Lesluyes, Fernanda M Amary, Roberto Tirabosco, Cristina Naceur‐Lombardelli, Sonya Hessey et al. · 2025 · Genome biology
  84. Supratentorial multifocal gliomas associated with Ollier disease harboring IDH1 R132H mutation: A case report
    Hiroshi Ikeda, Shigeru Yamaguchi, Yukitomo Ishi, Kento Wakabayashi, Ai Shimizu, Hiromi Kanno‐Okada, Takeshi Endo, Mitsutoshi Ota, Michinari Okamoto, Hiroaki Motegi et al. · 2023 · Neuropathology
  85. Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets
    Marc El Beaino, Syed T. Hoda, Ahmed J. Eldeib, Karim Z. Masrouha · 2023 · Current Oncology Reports
  86. Diagnostics of IDH1/2 Mutations in Intracranial Chondroid Tumors: Comparison of Molecular Genetic Methods and Immunohistochemistry
    V. O. Varachev, A. P. Shekhtman, D. A. Guskov, Дмитрий Викторович Рогожин, Alexander S. Zasedatelev, Tatiana V. Nasedkina · 2024 · Diagnostics
  87. The CFDE Workbench: Integrating Metadata and Processed Data from Common Fund Programs
    John Erol Evangelista, Daniel J.B. Clarke, Zhuorui Xie, Stephanie Olaiya, 김희수, Giacomo B. Marino, Anna I. Byrd, Shivaramakrishna Srinivasan, Sumana Srinivasan, Mano Ram Maurya et al. · 2026 · Journal of Molecular Biology
  88. Categorization of cancer through genomic complexity could guide research and management strategies
    Hugo M. Horlings, Adrienne Margaret Flanagan, David D. Huntsman · 2015 · The Journal of Pathology
  89. Conventional Chondrosarcoma with Clear Cell Features in the Rib: Report of Two Cases and Review of the Literature
    Sintawat Wangsiricharoen, Hulai Jalloh, Aaron Watkins James, Edward F. McCarthy, Carol D. Morris, John M. Gross · 2022 · International Journal of Surgical Pathology
  90. A new scoring system for the grading of conventional chondrosarcoma: Its clinicopathological significance
    Yosuke Susuki, Yuichi Yamada, Yoshihiro Ito, Kengo Kawaguchi, Hiroshi Furukawa, Kenichi Kohashi, Izumi Kinoshita, Kenichi Taguchi, Yasuharu Nakashima, Yoshinao Oda · 2022 · Pathology - Research and Practice
  91. Chondroblastoma of foot bones; a clinicopathological study of 29 cases confirming the diagnostic utility of H3K36M and H3G34W antibodies at an uncommon site
    Muhammad Usman Tariq, Nasir Ud Din, Madiha Bilal Qureshi, Yong-Koo Park · 2023 · Annals of Diagnostic Pathology
  92. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation
    Makoto Emori, Naoya Nakahashi, Akira Takasawa, Kenji Murata, Yasutaka Murahashi, Junya Shimizu, Tomohide Tsukahara, Shintaro Sugita, Kohichi Takada, Tadashi Hasegawa et al. · 2023 · Human Cell
  93. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience
    Elisabetta Setola, Stefania Benini, Alberto Righi, Gabriella Gamberi, Elisa Carretta, Cristina Ferrari, Sofia Avnet, Emanuela Palmerini, Giovanna Magagnoli, Marco Gambarotti et al. · 2023 · BMC Cancer
  94. Sustainable release of phosphorus under heavy metal stresses: From microbiology to productivity
    Da Tian, Hongjian Gao, Chaochun Zhang, Xinxin Ye · 2024 · Elsevier eBooks
  95. Benign cartilage tumors
    Jasvir S. Khurana, Edward F. McCarthy · 2014 · Diagnostic histopathology
  96. Bone Sarcomas and Desmoids
    Jeremy M. Brownstein, Thomas F. DeLaney · 2019 · Hematology/Oncology Clinics of North America
  97. Molekulare Pathologie in der Diagnostik der Knochentumoren: Aktueller Stand
    Daniel Baumhoer, Sylvia Höller · 2020 · Der Pathologe
  98. Acral FibroChondroMyxoid tumor: imaging features of a new entity
    Thomas Le Corroller, Nicolas Macagno, Hugo Nihous, Pierre Champsaur, Corinne Bouvier · 2020 · Skeletal Radiology
  99. Pathology of pleomorphic/undifferentiated and dedifferentiated bone neoplasms
    Iva Brčić, Andrew Eric Rosenberg · 2021 · Seminars in Diagnostic Pathology
  100. Evaluation of two new highly multiplexed PCR assays as an alternative to next‐generation sequencing for IDH1/2 mutation detection
    Loëtitia Favre, Nouhoum Sako, Sihem Tarfi, Violaine Tran Quang, Corine Joy, Aurélie Dupuy, Erell Guillerm, Philippe Gaulard, Orianne Wagner‐Ballon, Anaïs Pujals et al. · 2022 · Molecular Oncology